Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Argus Health
Johnson and Johnson
Citi
UBS
Express Scripts
Mallinckrodt
Queensland Health
Teva

Generated: December 13, 2018

DrugPatentWatch Database Preview

DOTAREM Drug Profile

« Back to Dashboard

Which patents cover Dotarem, and what generic alternatives are available?

Dotarem is a drug marketed by Guerbet and is included in one NDA.

The generic ingredient in DOTAREM is gadoterate meglumine. One supplier is listed for this compound. Additional details are available on the gadoterate meglumine profile page.

Drug patent expirations by year for DOTAREM
Generic Entry Opportunity Date for DOTAREM
Generic Entry Date for DOTAREM*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DOTAREM

US Patents and Regulatory Information for DOTAREM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-005 Mar 31, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-004 Mar 20, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-002 Mar 20, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-004 Mar 20, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-005 Mar 31, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
Teva
Argus Health
Moodys
Dow
Baxter
US Department of Justice
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.